The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.

J Hematol Oncol · 2014 · PMC4022142 · PMID 24739401

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

only marginally significantp = 0.050actually significant

CD44v6 positivity also correlated with poor prognosis, although the trend was only marginally significant (OS: p = 0.050; EFS: P = 0.058, Figure 1 C and D).

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.